Therapeutic anticoagulation is indicated for a variety of circumstances and conditions in
several fields of medicine to prevent or treat venous and arterial thromboembolism …

Antiplatelet agents and anticoagulants are a mainstay for the prevention and treatment of
thrombosis. However, despite advances in antithrombotic therapy, a fundamental challenge …

Background Experimental data indicate that reducing factor XI levels attenuates thrombosis
without causing bleeding, but the role of factor XI in the prevention of postoperative venous …

Importance The efficacy of factor XIa inhibition for thromboprophylaxis is unknown.
Osocimab is a long-acting, fully human monoclonal antibody that inhibits factor XIa …

Background Activated coagulation factor XI (FXIa) contributes to the development and
propagation of thrombosis but plays only a minor role in hemostasis; therefore, it is an …

Abstract Background Coagulation factor XI (FXI) contributes to the development of
thrombosis but appears to play a minor role in hemostasis and is, therefore, an attractive …

Severe factor XI (FXI) deficiency is an injury-related bleeding disorder, common in
Ashkenazi Jews (with two mutations prevailing), but rare worldwide (with heterogeneous …

Central venous catheter thrombosis can cause venous obstruction and pulmonary
embolism. To determine the extent to which catheter thrombosis is triggered by the contact …

A thorough analysis of clinical trial data in the Ionis integrated safety database (ISDB) was
performed to determine if there is a class effect on platelet numbers and function in subjects …

The most commonly used anticoagulants produce therapeutic antithrombotic effects either
by inhibiting thrombin or factor Xa (FXa) or by lowering the plasma levels of the precursors of …